Exact Sciences(EXAS)
(EXAS)
Q4
58 dage siden‧1 t. 1 min
Ordredybde
Lukket
Antal
Køb
0
Sælg
Antal
0
Seneste handel
Tid | Pris | Antal | Købere | Sælgere |
---|---|---|---|---|
- | - | - | - |
Volumenvægtet gennemsnitspris
-VWAP
-Omsætning (USD)
101.592.815Mæglerstatistik
Ingen data fundet
Corporate Actions
Næste begivenhed | |
---|---|
2024 Q1 | 8. maj |
Tidligere begivenheder | ||
---|---|---|
2023 Q4 | 21. feb. | |
2023 Årsregnskab | 21. feb. | |
2023 Q3 | 1. nov. 2023 | |
2023 Q2 | 1. aug. 2023 | |
2023 Generalforsamling | 8. jun. 2023 |
Data hentes fra Morningstar, Quartr
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Q4
58 dage siden‧1 t. 1 min
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Corporate Actions
Næste begivenhed | |
---|---|
2024 Q1 | 8. maj |
Tidligere begivenheder | ||
---|---|---|
2023 Q4 | 21. feb. | |
2023 Årsregnskab | 21. feb. | |
2023 Q3 | 1. nov. 2023 | |
2023 Q2 | 1. aug. 2023 | |
2023 Generalforsamling | 8. jun. 2023 |
Data hentes fra Morningstar, Quartr
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- 28. mar.28. mar.Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire
- 19. nov. 2023 · Redigeret19. nov. 2023 · RedigeretProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5. nov. 20235. nov. 2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
- 23. jun. 202323. jun. 2023"Exact Sciences (EXAS) could eventually nab half of the colon cancer screening market, an analyst said after the company's next-generation Cologuard beat the original product in a study of 20,000 people." https://www.investors.com/news/technology/exas-stock-has-surged-since-october-why-this-news-could-stoke-it-again/?src=A00220
- Brøt denne akkurat ut av den fallende trenden nå?
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Q4
58 dage siden‧1 t. 1 min
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- 28. mar.28. mar.Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire
- 19. nov. 2023 · Redigeret19. nov. 2023 · RedigeretProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5. nov. 20235. nov. 2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
- 23. jun. 202323. jun. 2023"Exact Sciences (EXAS) could eventually nab half of the colon cancer screening market, an analyst said after the company's next-generation Cologuard beat the original product in a study of 20,000 people." https://www.investors.com/news/technology/exas-stock-has-surged-since-october-why-this-news-could-stoke-it-again/?src=A00220
- Brøt denne akkurat ut av den fallende trenden nå?
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Lukket
Antal
Køb
0
Sælg
Antal
0
Seneste handel
Tid | Pris | Antal | Købere | Sælgere |
---|---|---|---|---|
- | - | - | - |
Volumenvægtet gennemsnitspris
-VWAP
-Omsætning (USD)
101.592.815Mæglerstatistik
Ingen data fundet
Corporate Actions
Næste begivenhed | |
---|---|
2024 Q1 | 8. maj |
Tidligere begivenheder | ||
---|---|---|
2023 Q4 | 21. feb. | |
2023 Årsregnskab | 21. feb. | |
2023 Q3 | 1. nov. 2023 | |
2023 Q2 | 1. aug. 2023 | |
2023 Generalforsamling | 8. jun. 2023 |
Data hentes fra Morningstar, Quartr